Nothing Special   »   [go: up one dir, main page]

MX2010009922A - Activadores de piridazinona glucocinasa. - Google Patents

Activadores de piridazinona glucocinasa.

Info

Publication number
MX2010009922A
MX2010009922A MX2010009922A MX2010009922A MX2010009922A MX 2010009922 A MX2010009922 A MX 2010009922A MX 2010009922 A MX2010009922 A MX 2010009922A MX 2010009922 A MX2010009922 A MX 2010009922A MX 2010009922 A MX2010009922 A MX 2010009922A
Authority
MX
Mexico
Prior art keywords
pyridazinone
glucokinase activators
compounds
disorders
substituents
Prior art date
Application number
MX2010009922A
Other languages
English (en)
Inventor
Jefferson Wright Tilley
Robert Francis Kester
Nancy-Ellen Haynes
Yimin Qian
Nathan Robert Scott
Steven Joseph Berthel
Lee Apostle Mcdermott
Ramakanth Sarabu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010009922A publication Critical patent/MX2010009922A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan aquí compuestos de fórmula (1) (ver fórmula (I)) en los que X, Y, Q y R1 a R3 se definen en la especificación, así como sales farmacéuticamente aceptables de los mismos, en los que los sustituyentes son como los que se describen en la especificación. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades metabólicas y trastornos como, por ejemplo, diabetes mellitus de tipo II.
MX2010009922A 2008-04-16 2009-04-06 Activadores de piridazinona glucocinasa. MX2010009922A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4531808P 2008-04-16 2008-04-16
US11465408P 2008-11-14 2008-11-14
PCT/EP2009/054058 WO2009127544A1 (en) 2008-04-16 2009-04-06 Pyridazinone glucokinase activators

Publications (1)

Publication Number Publication Date
MX2010009922A true MX2010009922A (es) 2010-09-28

Family

ID=40666944

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009922A MX2010009922A (es) 2008-04-16 2009-04-06 Activadores de piridazinona glucocinasa.

Country Status (14)

Country Link
US (1) US8258134B2 (es)
EP (1) EP2268633A1 (es)
JP (1) JP5301655B2 (es)
KR (1) KR101270389B1 (es)
CN (1) CN102007116B (es)
AR (1) AR071323A1 (es)
AU (1) AU2009237792B2 (es)
BR (1) BRPI0911476A2 (es)
CA (1) CA2720559A1 (es)
IL (1) IL207349A (es)
MX (1) MX2010009922A (es)
PE (1) PE20091725A1 (es)
TW (1) TW200944517A (es)
WO (1) WO2009127544A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
CA2676173A1 (en) * 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
CA2967254C (en) 2008-02-29 2019-03-26 Lantheus Medical Imaging, Inc. Contrast agents for applications including imaging cancer
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
EP4046990A1 (en) 2010-02-08 2022-08-24 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TWI566663B (zh) * 2011-03-15 2017-01-11 鴻海精密工業股份有限公司 鎖扣組件、帶有鎖扣組件的載具及電路板固定系統
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
RU2664329C1 (ru) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
JP6785838B2 (ja) 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 新規な置換グリシン誘導のｆｘｉａ阻害剤
AR127064A1 (es) * 2021-09-15 2023-12-13 Hua Medicine Shanghai Ltd Prodroga de derivados de pirrolidona como activador de glucoquinasa
WO2024132901A1 (en) * 2022-12-19 2024-06-27 Syngenta Crop Protection Ag Microbiocidal pyridazine dihydrooxadiazine derivatives
WO2024188273A1 (zh) * 2023-03-13 2024-09-19 华领医药技术（上海）有限公司 作为葡萄糖激酶激活剂的吡咯烷酮衍生物的固体形式

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2226811T3 (es) 1999-03-29 2005-04-01 F. Hoffmann-La Roche Ag Activadores de glucoquinasa.
AU2001252270B2 (en) * 2000-05-03 2005-12-15 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
KR100502033B1 (ko) 2000-05-03 2005-07-25 에프. 호프만-라 로슈 아게 알키닐 페닐 헤테로방향족 글루코키나제 활성제
CN1245394C (zh) 2000-05-08 2006-03-15 霍夫曼-拉罗奇有限公司 作为葡糖激酶激活剂的取代的苯乙酰胺及其用途
PT1283830E (pt) 2000-05-08 2008-08-18 Hoffmann La Roche Activadores da glucoquinase de fenilamida substituída com para-amino
CA2429642C (en) 2000-12-06 2007-11-20 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1458382A1 (en) * 2001-12-21 2004-09-22 Novo Nordisk A/S Amide derivatives as gk activators
ATE346056T1 (de) 2002-04-26 2006-12-15 Hoffmann La Roche Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren
GB0210762D0 (en) * 2002-05-10 2002-06-19 Glaxo Group Ltd Compounds
CA2498089A1 (en) 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GT200300283A (es) * 2002-12-12 2004-07-14 Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
AR045414A1 (es) 2003-02-13 2005-10-26 Banyu Pharma Co Ltd Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
CA2516407C (en) 2003-02-26 2013-07-09 Banyu Pharmaceutical Co., Ltd. Heteroarylcarbamoylbenzene derivatives
KR20070007104A (ko) 2004-02-18 2007-01-12 아스트라제네카 아베 화합물
EP2048137A1 (en) 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
CA2560286A1 (en) 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
CN1960995B (zh) 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
WO2005103021A1 (en) 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
CA2576407A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR101066882B1 (ko) 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. 헤테로방향족 글루코키나제 활성화제
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2305674A1 (en) 2005-07-09 2011-04-06 AstraZeneca AB Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1910350A1 (en) 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
WO2007007886A1 (en) 2005-07-11 2007-01-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
RU2008112184A (ru) 2005-08-31 2009-10-10 Астеллас Фарма Инк. (Jp) Производное тиазола
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
AU2006310474A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
AU2006310475A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
DK2463283T3 (da) 2006-04-20 2014-08-18 Pfizer Prod Inc Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme
KR20080042286A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리다지논 구조를 포함하는 캐스파제 저해제
CL2008002703A1 (es) * 2007-09-14 2009-11-20 Sumitomo Chemical Co Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios.
RU2010121763A (ru) * 2007-10-31 2011-12-10 Ниссан Кемикал Индастриз, Лтд. (Jp) Производные пиридазинона и ингибиторы р2х7 рецептора
WO2009142732A2 (en) * 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase

Also Published As

Publication number Publication date
BRPI0911476A2 (pt) 2019-03-19
IL207349A (en) 2014-08-31
JP2011516592A (ja) 2011-05-26
KR101270389B1 (ko) 2013-06-05
WO2009127544A1 (en) 2009-10-22
KR20100124328A (ko) 2010-11-26
CN102007116B (zh) 2014-10-22
CN102007116A (zh) 2011-04-06
US20090264434A1 (en) 2009-10-22
IL207349A0 (en) 2010-12-30
JP5301655B2 (ja) 2013-09-25
CA2720559A1 (en) 2009-10-22
AU2009237792A1 (en) 2009-10-22
AR071323A1 (es) 2010-06-09
EP2268633A1 (en) 2011-01-05
AU2009237792B2 (en) 2014-07-24
US8258134B2 (en) 2012-09-04
PE20091725A1 (es) 2009-11-13
TW200944517A (en) 2009-11-01

Similar Documents

Publication Publication Date Title
MX2010009922A (es) Activadores de piridazinona glucocinasa.
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
TW200643013A (en) Pyrazoles
GEP20146125B (en) Aminopyrimidines as syk inhibitors
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MY153258A (en) Pyrazinone derivatives and their use inthe threatment of lung diseases
GEP20125487B (en) Organic compounds and their use
TW200833675A (en) Nicotinamide derivatives
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
GEP20156351B (en) Glucagon receptor modulator
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
HK1125358A1 (en) Substituted cyclohexylmethyl derivatives
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
IN2012DN03182A (es)
MX2009013501A (es) Compuestos piperidinicos y sus usos.
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.

Legal Events

Date Code Title Description
FG Grant or registration